Evidence map›Paper›PMID 40568574›Full record

ArticleFrontiers in immunology2025

Kyosuke Kobayashi, Yuri Imai, Yuka Shimizu, Isamu Ogawa, Takaaki Nakai, Yuri Mizuno, Yoshika Kaneda, Yumiko Watanabe-Yasuoka, Fuka Yamazaki, Junko Mochizuki and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kyosuke Kobayashi *Wellness Science Labs, Meiji Holdings Co., Ltd., Tokyo, Japan.
Yuri Imai *Education and Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan.
Yuka Shimizu *Education and Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan.
Isamu OgawaDepartment of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan.
Takaaki NakaiDepartment of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan.
Yuri MizunoEducation and Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan.
Yoshika KanedaEducation and Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan.
Yumiko Watanabe-YasuokaWellness Science Labs, Meiji Holdings Co., Ltd., Tokyo, Japan.
Fuka YamazakiWellness Science Labs, Meiji Holdings Co., Ltd., Tokyo, Japan.
Junko MochizukiHealth Science Research Unit, R&D Division, Meiji Co., Ltd., Tokyo, Japan.
Toshihiro SashiharaWellness Science Labs, Meiji Holdings Co., Ltd., Tokyo, Japan.
Tamihide MatsunagaEducation and Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan.
Takahiro IwaoEducation and Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lactic acid bacteria (LAB) have been widely used as probiotics which contribute to our health. We previously reported that Methods: A hiPSC-SI and LAB co-culture model was established to assess the impact of LAB on barrier function and elucidate the underlying mechanisms. Results: The medium on the luminal side for co-culturing cells and bacteria was examined and determined to use Hanks' balanced salt solution without glucose in terms of bacterial survival rate. LAB were found to ameliorate permeability and decrease the gene expression of tight junction associated proteins induced by TNF-α and IFN-γ. Regarding cell differentiation, LAB suppressed the downregulation of Conclusions: The results indicate that LAB ameliorate the cytokine-induced dysfunction of intestinal barrier integrity and homeostasis disrupted by cytokines in a co-culture model of hiPSC-SI and LAB.

Indexed as

Induced Pluripotent Stem CellsIntestinal MucosaIntestine, SmallLactobacillus delbrueckiiProbioticsStreptococcus thermophilusCaco-2 CellsCell DifferentiationCoculture TechniquesHumansTumor Necrosis Factor-alphaTumor Necrosis Factor-alphaanti-inflammationbarrier functiondifferentiationinduced pluripotent stem cell-derived crypt-villus structural small intestinelactic acid bacteriamucin 2tight junction

Identifiers

PMID40568574
PMCPMC12190435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.